ABSTRACT
Objective To explore the predictive value of 18F-fluorodeoxyglucose (FDG) PET/CT related metabolic parameters for Kras mutation in colorectal cancer (CRC) patients.Methods Retrospective analysis was conducted in 150 patients (105 males,45 females,median age:63 years) with CRC who underwent 18F-FDG PET/CT in Changhai Hospital of Navy Medical University between November 2011 and August 2017.The primary tumors were removed by surgery and patients received genetic testing within 1 month after PET/CT.18F-FDG PET/CT related metabolic parameters were measured,including maximum standardized uptake value (SUVmax),metabolic tumor volume (MTV;including MTV2.5,MTV20％,MTV30％,MTV40％,MTV50％),total lesion glycolysis (TLG;including TLG2.5,TLG20％,TLG30％,TLG40％,TLG50％).Logistic regression analysis and receiver operating characteristic (ROC) curve analysis were used to analyze the data.Results There were 78 Kras-mutated type patients and 72 wild-type patients.Logistic regression analysis showed that SUVmax (odds ratio (OR) =1.176,95％ CI:1.043-1.327) and MTV2.5 (OR =1.125,95 ％ CI:1.002-1.263) were predictors of Kras mutation.With SUVmax =15.5 and MTV2.5 =23.79 cm3 as the cut-off value,the prediction accuracies of Kras mutation were 67.33％(101/150) and 65.33％(98/150),respectively.The accuracies of SUVmax and MTV2.5 for predicting Kras mutation were higher in recta or sigmoid colon cancers (70.79％(63/89) and 68.54％(61/89)).Conclusion SUVmax and MTV2.5 can predict Kras mutation in CRC patients,but there is a significant gap of predictive efficiency between PET/CT and gene detection.
ABSTRACT
OBJECTIVE:To exlpore the effect of telmisartan combine with benazepril on plasma brain natriuretic peptide (BNP) of patients underwent permanent cardiac pacemaker implantation. METHODS:96 patients underwent permanent cardiac pacemaker implantation were randomly divided into group A,B and C with 32 cases in each group. Based on routine treatment, group A was given telmisartan 80 mg/d immediately after operation,qd,group B given benazepril 10 mg/d,qd,group C given telmisartan 40 mg/d+ benazepril 10 mg/d,qd. All of them was given medicine for 6 months. LEVF,CI,Ren,BNP,AngⅡ and Ald were compared among 3 groups. RESULTS:After 6 months,BNP levels of 3 groups were higher than before,with statistical significance (P0.05);those of group A and B were decreased,with statistical significance(P<0.05);those of group C were higher than those of group A and B, with statistical significance(P<0.05). The levels of Ren,AngⅡ and Ald in 3 groups were decreased after treatment,with statisti-cal significance (P<0.05);those of group C were lower than those of group A and B,with statistical significance (P<0.05). CONCLUSIONS:Telmisartan combined with benazepril can improve ventricular remodeling and heart function,and reduce plasma BNP levels in patients underwent permanent cardiac pacemaker implantation.